A case of synchronous bilateral calyx urothelial carcinoma: combined treatment approach

Authors

  • S. Semko Department of Plastic and Reconstructive Oncourology, National Cancer Institute, Kyiv 03022, Ukraine
  • M. Pikul Department of Plastic and Reconstructive Oncourology, National Cancer Institute, Kyiv 03022, Ukraine
  • O. Voylenko Department of Plastic and Reconstructive Oncourology, National Cancer Institute, Kyiv 03022, Ukraine
  • O. Stakhovskyi Department of Plastic and Reconstructive Oncourology, National Cancer Institute, Kyiv 03022, Ukraine
  • O. Kononenko Department of Plastic and Reconstructive Oncourology, National Cancer Institute, Kyiv 03022, Ukraine
  • Yu. Vitruk Department of Plastic and Reconstructive Oncourology, National Cancer Institute, Kyiv 03022, Ukraine
  • E. Stakhovsky Department of Plastic and Reconstructive Oncourology, National Cancer Institute, Kyiv 03022, Ukraine

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12791

Keywords:

bilateral urothelial cancer, kidney sparing surgery, upper urinary tract urothelial carcinoma

Abstract

Summary. Upper urinary tract urothelial carcinoma is a rare tumor. Data about its correct management are controversial. Investigational technology development made it possible to diagnose asymptomatic small tumors, which can be successfully managed endoscopically. We report the case of bilateral urothelial cancer and hydronephrosis in patient aged 38. After management of acute post-renal kidney insufficiency, the neoadjuvant platinum-based chemotherapy was used followed by the kidney-sparing surgery split in two interventions on both sides. The patient does not have any relapse or further progression after one year of initial treatment with good performance status and high life quality level. We believe that the kidney preserving strategy can be considered as an option even in high-risk patients. The renal function in such cases is a crucial parameter affecting the outcome.

References

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017; 35: 379–87.

Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol 2008; 53: 720–31.

Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224–33.

Leow JJ, Martin-Doyle W, Fay AP, et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014; 66: 529–41.

Hosogoe S, Hatakeyama S, Kusaka A, et al. Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 2018; 4: 946–53.

Yakoubi R, Colin P, Seisen T, et al. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 2014; 40: 1629–34.

Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013; 63: 1059–71.

Downloads

Published

08.06.2023

How to Cite

Semko, S., Pikul, M., Voylenko, O., Stakhovskyi, O., Kononenko, O., Vitruk, Y., & Stakhovsky, E. (2023). A case of synchronous bilateral calyx urothelial carcinoma: combined treatment approach. Experimental Oncology, 41(1), 76–79. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12791

Issue

Vol. 41 No. 1 (2019): Experimental Oncology

Section

Case report

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)